The Lupus Foundation of America-Rapid Evaluation of Activity in Lupus Clinician-Reported Outcome Predicts Damage in Patients With Systemic Lupus Erythematosus. Data From the Almenara Lupus Cohort
- PMID: 38880959
- DOI: 10.1097/RHU.0000000000002102
The Lupus Foundation of America-Rapid Evaluation of Activity in Lupus Clinician-Reported Outcome Predicts Damage in Patients With Systemic Lupus Erythematosus. Data From the Almenara Lupus Cohort
Abstract
Objective: To evaluate the predictive value of the LFA-REAL ClinRO (Lupus Foundation of America Rapid Evaluation of Activity in Lupus clinician-reported outcome) on damage accrual in systemic lupus erythematosus patients.
Methods: Data from a prevalent lupus cohort were used. The LFA-REAL ClinRO includes 9 domains: mucocutaneous (global and 3 subdomains), musculoskeletal (global and 2 subdomains), cardiorespiratory, neuropsychiatric, renal, hematological, constitutional, vasculitis, and other (it allows for other or rare manifestations). For each domain, a 0- to 100-mm visual analog scale is used, and global domains are included except for the mucocutaneous and musculoskeletal domains where the subdomains are included; it allows for 3 manifestations under "other," so the score ranges from 0 to 1400 (sum of 14 in the visual analog scale). Damage was assessed with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index. Generalized estimating equations were performed, being the outcome the increase in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index; confounders from the previous visit were included; adjusted multivariable models were done. Incidence rate ratios per 10-unit increase in the LFA-REAL ClinRO were reported. Similar models were performed to evaluate the impact of the SLEDAI-2K (SLE Disease Activity Index) and physician global assessment on damage to determine which measure would better predict damage accrual.
Results: Three-hundred thirty-one patients and 1425 visits were included, 1.9 (SD 1.2) years of follow-up. Disease duration at baseline was 10.7 (7.4) years. The mean LFA-REAL ClinRO was 18.2 (SD 30.7). During the follow-up visits, 63 (17.9%) patients accrued damage once; 4 (1.1%) accrued damage twice. The LFA-REAL ClinRO was predictive of damage accrual even after adjustment for possible confounders (incidence rate ratio 1.10 (95% confidence interval 1.04-1.16; p < 0.001). Similar results were obtained using the SLEDAI-2K and the physician global assessment.
Conclusion: The LFA-REAL ClinRO is predictive of damage accrual, even after adjusting for possible confounders.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
M.F.U.-G. has grant support from Janssen and Pfizer, has been speaker for GSK and AztraZeneca, and has been member of the advisory boards for AztraZeneca and Ferrer; R.V.G.-C. has grant support from Pfizer; C.R.-S. and V.R.P.-Q. have grant support from Janssen. The other authors declare no conflict of interest.
Similar articles
-
Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort.Lupus Sci Med. 2025 Jul 30;12(2):e001570. doi: 10.1136/lupus-2025-001570. Lupus Sci Med. 2025. PMID: 40738509 Free PMC article.
-
Self-efficacy is associated with a lower probability of damage accrual in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort.Clin Exp Rheumatol. 2025 Jun 18. doi: 10.55563/clinexprheumatol/fdf5zj. Online ahead of print. Clin Exp Rheumatol. 2025. PMID: 40556606
-
Systemic Lupus International Collaborating Clinics-Frailty Index predicts hospitalisations in the Almenara Lupus Cohort.Lupus Sci Med. 2025 Jul 13;12(2):e001624. doi: 10.1136/lupus-2025-001624. Lupus Sci Med. 2025. PMID: 40659389 Free PMC article.
-
Smoking and Its Association With Morbidity in Systemic Lupus Erythematosus Evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index: Preliminary Data and Systematic Review.Arthritis Rheumatol. 2016 Feb;68(2):441-8. doi: 10.1002/art.39427. Arthritis Rheumatol. 2016. PMID: 26359794
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum . 1992;35:630–640.
-
- Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol . 2002;29:288–291.
-
- Guzmán J, Cardiel MH, Arce-Salinas A, et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol . 1992;19:1551–1558.
-
- Ibañez D, Gladman D, Urowitz M. Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J Rheumatol . 2007;34:336–340.
-
- Garcia MA, Alba P, Del Campo-Perez V, et al. Multicenter lupus register from Argentina, the RELESSAR database: influence of ethnicity on disease phenotype. Lupus . 2022;31:637–645.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical